Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving

StatusRecruiting
PhasePhase 2/3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 5 more changesShow less
    • Start date: Oct 1, 2026 to Nov 1, 2026
    • Eligibility criteria expanded, about 344 words
    • Secondary endpoints: details revised at 8 of 8 entries
    • Site details revised
    • Study description expanded, about 2 words
  2. Start date: Aug 1, 2026 to Oct 1, 2026v7
  3. Primary completion pushed from Oct 2030 to Oct 31, 2030v6
  4. Start date: Jun 1, 2026 to Aug 1, 2026v5
  5. Start date: Apr 1, 2026 to Jun 1, 2026v4
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Jan 15, 2026 to Apr 1, 2026v3
  2. Start date: Dec 1, 2025 to Jan 15, 2026v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Cannabidiol (CBD), one of the most prevalent cannabinoids in cannabis (marijuana) has been shown to reduce alcohol withdrawal symptoms in laboratory animals. In people without alcohol use disorder (AUD), CBD has been show to be effective in reducing anxiety, sleep problems, and seizures; all of these are common symptoms of alcohol withdrawal. This randomized placebo-controlled clinical trial will evaluate the potential of CBD to improve alcohol withdrawal symptoms and reduce craving during acute abstinence among individuals with moderate-to-severe AUD. Adult participants with moderate-to-severe AUD will be admitted to an inpatient research unit at the Johns Hopkins Hospital for a 5-day, 4-night stay that includes alcohol abstinence with management of their alcohol withdrawal. In addition to standard care, participants will receive CBD or placebo (no CBD), complete assessments of withdrawal, sleep quality and provide breath and blood samples.
Trial Details
NCT Number NCT07148843
Lead Sponsor Johns Hopkins University
Collaborators: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Conditions
(from sponsor)		 Alcohol Use Disorder (AUD), Withdrawal From Addictive Substance; Detoxification, Craving
Related terms Alcohol Abstinence, Alcoholism
Enrollment 105 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov